查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
化脓性汗腺炎:KOL的洞察
年间契约型资讯服务
商品编码
1524360

化脓性汗腺炎:KOL的洞察

Hidradenitis Suppurativa - KOL Insight
出版日期: 年间契约型资讯服务 | 出版商: FirstWord Group | 英文

价格
简介目录

随着治疗方案的显着进步，化脓性汗腺炎 (HS) 的治疗模式正在迅速发展。本报告根据主要 KOL 的见解，对热射病目前和未来的治疗状况进行了全面分析。特别是艾伯维的Humira（阿达木单抗）作为一线生物疗法的关键作用、诺华的Cosentyx（苏金单抗）对阿达木单抗无反应/不能耐受的患者的承诺，以及UCB 的Bimzelx （bimekizumab）。我们还考虑了 HS 治疗演算法的进展及其对临床实践和药物开发的影响。

本报告回答的关键问题：

  • TNF 抑制剂（例如艾伯维的 Humira（阿达木单抗）和强生/默克公司的 Remicade（英夫利西单抗））在目前的 HS 治疗中发挥什么作用？另外，预计会有哪些变化？
  • 诺华 Cosentyx（苏金单抗）等二线治疗方案对于对阿达木单抗无反应或不能耐受的患者效果如何？
  • UCB 的 Bimzelx (bimekizumab) 在治疗 HS 方面的新潜力以及 III 期临床试验数据显示了什么？
  • 治疗 HS 的主要生物製剂的疗效和安全性如何？
  • 随着新疗法的推出，治疗范式预计将如何发展？
  • 关键 KOL（关键意见领袖）对 HS 目前和未来的管理策略有何看法？
  • 现有的和新的热射病治疗方法的使用预计会发生哪些变化？
  • 这些发展对 HS 管理的临床实务和药物开发有何策略影响？

本报告的调查对象的领导品牌

  • Humira (adalimumab)
  • Cosentyx (secukinumab)
  • Bimzelx (bimekizumab)
  • Izokibep
  • Sonelokimab
  • Povorcitinib
  • Rinvoq (upadacitinib)
  • Opzelura (ruxolitinib)
  • Brepocitinib
  • Sotyktu (deucravacitinib)
  • Lutikizumab
  • Spevigo (spesolimab)
  • Orismilast
  • Amlitelimab
  • Amlitelimab
  • SAR442970
  • Eltrekibart
  • MC2-32
  • Remibrutinib
  • MAS825
  • lys006
  • Iscalimab
  • Ianalumab
  • Tavneos (avacopan)
  • KT-474
  • PTM-001

调查对象企业

  • AbbVie
  • Amgen
  • Novartis
  • Lilly
  • Sanofi
  • UCB
  • Merck & Co.
  • Bristol Myers Squibb
  • Incyte
  • Boehringer Ingelheim
  • Affibody
  • Johnson & Johnson
  • ACELYRIN
  • Moonlake Immunotherapeutics
  • UNION Therapeutics
  • Phoenicis Therapeutics
  • Kymera Therapeutics
  • Priovant Therapeutics
  • MC2 Therapeutics

目录

摘要整理

现在·未来的治疗流程

调查目的

TNF抑制剂

  • 认证核可药
    • Humira (Adalimumab;AbbVie)，Remicade (Infliximab;Johnson & Johnson/Merck & Co.)

IL-17抑制剂

  • 认证核可药
    • Cosentyx (Secukinumab;Novartis)
    • Bimzelx (bimekizumabu;UCB)
  • 开发平台(管线)医药品
    • izokibeppu (Affibody/ACELYRIN)
    • sonerokimabu (MoonLake Immunotherapeutics)

JAK/TYK2抑制剂

  • 开发平台(管线)医药品
    • Povorcitinib (INCB54707;Incyte)
    • Rinvoq (Upadacitinib;AbbVie)
    • Opzelura (rukisorichinibu;Incyte)
    • bureposhichinibu (Priovant Therapeutics)
    • Sotyktu (deyukurabashichinibu;Incyte)

其他的作用机制

  • 开发平台(管线)医药品
    • Lutikizumab (ABT-981; AbbVie)
    • Spevigo (spesolimab; Boehringer Ingelheim)
    • Orismilast (UNION Therapeutics)
    • Amlitelimab and SAR442970 (Sanofi)
    • Eltrekibart (LY3041658; Lilly)
    • MC2-32 (RGRN-305; MC2 Therapeutics)
    • Remibrutinib, MAS825, LYS006, iscalimab and ianalumab (Novartis)
    • Tavneos (avacopan; Amgen)
    • KT-474 (Kymera Therapeutics/Sanofi)
    • PTM-001 (Phoenicis Therapeutics)

今后的治疗趋势

  • 主要的考察:摘要

附录

  • KOL详细内容
    • 美国的KOL
    • 欧洲的KOL
简介目录

The treatment landscape for hidradenitis suppurativa (HS) is rapidly evolving with significant advancements in therapeutic options. Insights from leading KOLs provide a comprehensive review of the current and future treatment landscape for HS, highlighting the pivotal role of AbbVie's Humira (adalimumab) as the primary first-line biologic treatment, the promise of Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab, and the emerging potential of UCB's Bimzelx (bimekizumab). Explore the evolving HS treatment algorithms and the implications for clinical practice and drug development.

Key questions answered:

  • What is the current role of TNF inhibitors, such as Abbvie's Humira (adalimumab) and Johnson & Johnson/Merck & Co.'s Remicade (infliximab), in the treatment of HS? What changes are anticipated in their usage?
  • How effective are secondary treatment options like Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab?
  • What is the emerging potential of UCB's Bimzelx (bimekizumab) in the HS treatment landscape, and what do the Phase III trial data suggest?
  • What are the key efficacy and safety profiles of the leading biologic treatments for HS?
  • How are treatment paradigms expected to evolve with the introduction of new therapies?
  • What insights do leading Key Opinion Leaders (KOLs) provide on the current and future management strategies for HS?
  • What are the anticipated changes in the usage of existing and emerging treatments for HS?
  • What are the strategic implications of these developments for clinical practice and drug development in HS management?

Key brands covered in this report:

  • Humira (adalimumab)
  • Cosentyx (secukinumab)
  • Bimzelx (bimekizumab)
  • Izokibep
  • Sonelokimab
  • Povorcitinib
  • Rinvoq (upadacitinib)
  • Opzelura (ruxolitinib)
  • Brepocitinib
  • Sotyktu (deucravacitinib)
  • Lutikizumab
  • Spevigo (spesolimab)
  • Orismilast
  • Amlitelimab
  • SAR442970
  • Eltrekibart
  • MC2-32
  • Remibrutinib
  • MAS825
  • lys006
  • Iscalimab
  • Ianalumab
  • Tavneos (avacopan)
  • KT-474
  • PTM-001

Companies:

  • AbbVie
  • Amgen
  • Novartis
  • Lilly
  • Sanofi
  • UCB
  • Merck & Co.
  • Bristol Myers Squibb
  • Incyte
  • Boehringer Ingelheim
  • Affibody
  • Johnson & Johnson
  • ACELYRIN
  • Moonlake Immunotherapeutics
  • UNION Therapeutics
  • Phoenicis Therapeutics
  • Kymera Therapeutics
  • Priovant Therapeutics
  • MC2 Therapeutics

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

TNF inhibitors

  • Approved drugs
    • Humira (adalimumab; AbbVie) and Remicade (infliximab; Johnson & Johnson/Merck & Co.)

IL-17 inhibitors

  • Approved drugs
    • Cosentyx (secukinumab; Novartis)
    • Bimzelx (bimekizumab; UCB)
  • Pipeline drugs
    • Izokibep (Affibody/ACELYRIN)
    • Sonelokimab (MoonLake Immunotherapeutics)

JAK/TYK2 inhibitors

  • Pipeline drugs
    • Povorcitinib (INCB54707; Incyte)
    • Rinvoq (upadacitinib; AbbVie)
    • Opzelura (ruxolitinib; Incyte)
    • Brepocitinib (Priovant Therapeutics)
    • Sotyktu (deucravacitinib; Bristol Myers Squibb)

Other mechanisms of action

  • Pipeline drugs
    • Lutikizumab (ABT-981; AbbVie)
    • Spevigo (spesolimab; Boehringer Ingelheim)
    • Orismilast (UNION Therapeutics)
    • Amlitelimab and SAR442970 (Sanofi)
    • Eltrekibart (LY3041658; Lilly)
    • MC2-32 (RGRN-305; MC2 Therapeutics)
    • Remibrutinib, MAS825, LYS006, iscalimab and ianalumab (Novartis)
    • Tavneos (avacopan; Amgen)
    • KT-474 (Kymera Therapeutics/Sanofi)
    • PTM-001 (Phoenicis Therapeutics)

Future treatment trends

  • Key insights summary

Appendix

  • KOL details
    • KOLs from the USA
    • KOLs from Europe